Data updated: Mar 10, 2026
KYNMOBI
APOMORPHINE HYDROCHLORIDE
Approved 2020-05-21
2
Indications
--
Phase 3 Trials
5
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2020-05-21
- Routes
- SUBLINGUAL
- Dosage Forms
- FILM
KYNMOBI Approval History
Loading approval history...
What KYNMOBI Treats
2 FDA approvalsOriginally approved for its first indication in 2020 . Covers 2 distinct patient populations.
- Other (2)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
KYNMOBI FDA Label Details
ProKYNMOBI Patents & Exclusivity
Latest Patent: Apr 2036
Patents (300 active)
US10449146
Expires Apr 19, 2036
US10959943
Expires Apr 19, 2036
US11419769
Expires Dec 16, 2031
US8414922
Expires Dec 16, 2031
US8846074
Expires Dec 16, 2031
US9669021
Expires Jun 11, 2030
US9669019
Expires Jun 11, 2030
US9283219
Expires Jun 11, 2030
US10420763
Expires Jun 11, 2030
US9326981
Expires Jun 11, 2030
+ 290 more patents
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.